This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Williams, A.
Right arrow Articles by Hill, A. V. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williams, A.
Right arrow Articles by Hill, A. V. S.

 Previous Article  |  Next Article 

Infection and Immunity, June 2005, p. 3814-3816, Vol. 73, No. 6
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.6.3814-3816.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Boosting with Poxviruses Enhances Mycobacterium bovis BCG Efficacy against Tuberculosis in Guinea Pigs

A. Williams,1,{dagger} N. P. Goonetilleke,2,{dagger} H. McShane,3 Simon O. Clark,1 Graham Hatch,1 S. C. Gilbert,2 and A. V. S. Hill2,3*

Health Protection Agency, Porton Down, Salisbury,1 Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN,2 Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, United Kingdom3

Received 23 August 2004/ Returned for modification 18 October 2004/ Accepted 20 December 2004

Tuberculosis is rising in the developing world due to poor health care, human immunodeficiency virus type 1 infection, and the low protective efficacy of the Mycobacterium bovis BCG vaccine. A new vaccination strategy that could protect adults in the developing world from tuberculosis could have a huge impact on public health. We show that BCG boosted by poxviruses expressing antigen 85A induced unprecedented 100% protection of guinea pigs from high-dose aerosol challenge with Mycobacterium tuberculosis, suggesting a strategy for enhancing and prolonging the efficacy of BCG.

* Corresponding author. Mailing address: Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, United Kingdom. Phone: 44 1865 287759. Fax: 44 1865 287686. E-mail: adrian.hill{at}well.ox.ac.uk.

Editor: J. D. Clements

{dagger} A.W. and N.P.G. are joint first authors.

Infection and Immunity, June 2005, p. 3814-3816, Vol. 73, No. 6
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.6.3814-3816.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Vordermeier, H. M., Villarreal-Ramos, B., Cockle, P. J., McAulay, M., Rhodes, S. G., Thacker, T., Gilbert, S. C., McShane, H., Hill, A. V. S., Xing, Z., Hewinson, R. G. (2009). Viral Booster Vaccines Improve Mycobacterium bovis BCG-Induced Protection against Bovine Tuberculosis. Infect. Immun. 77: 3364-3373 [Abstract] [Full Text]  
  • Cayabyab, M. J., Korioth-Schmitz, B., Sun, Y., Carville, A., Balachandran, H., Miura, A., Carlson, K. R., Buzby, A. P., Haynes, B. F., Jacobs, W. R., Letvin, N. L. (2009). Recombinant Mycobacterium bovis BCG Prime-Recombinant Adenovirus Boost Vaccination in Rhesus Monkeys Elicits Robust Polyfunctional Simian Immunodeficiency Virus-Specific T-Cell Responses. J. Virol. 83: 5505-5513 [Abstract] [Full Text]  
  • Hanke, T., McMichael, A. J., Dorrell, L. (2007). Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J. Gen. Virol. 88: 1-12 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»